UTHR Share Price

Open 120.51 Change Price %
High 120.70 1 Day -1.27 -1.06
Low 118.37 1 Week 0.00 0.00
Close 118.59 1 Month -1.92 -1.59
Volume 304002 1 Year -8.41 -6.62
52 Week High 169.89
52 Week Low 112.01
UTHR Important Levels
Resistance 2 120.75
Resistance 1 119.86
Pivot 119.22
Support 1 117.32
Support 2 116.43
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

United Therapeutics Corporation (NASDAQ: UTHR)

UTHR Technical Analysis 5
As on 31st Oct 2017 UTHR Share Price closed @ 118.59 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 133.55 & Strong Sell for SHORT-TERM with Stoploss of 123.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
UTHR Target for November
1st Target up-side 126.71
2nd Target up-side 132.4
3rd Target up-side 138.09
1st Target down-side 110.47
2nd Target down-side 104.78
3rd Target down-side 99.09
UTHR Other Details
Segment EQ
Market Capital 2447069440.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.unither.com
UTHR Address
UTHR
1040 Spring Street
Silver Spring, MD 20910
United States
Phone: 301-608-9292
Fax: 301-608-9291
UTHR Latest News
Interactive Technical Analysis Chart United Therapeutics Corporation ( UTHR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on United Therapeutics Corporation
UTHR Business Profile
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents, Cell-Based Therapy, and Engineered Lungs and Lung Tissue for Transplantation. Prostacyclin analogues are stable synthetic forms of prostacyclin. Its product is Remodulin (treprostinil) Injection (Remodulin). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of pulmonary arterial hypertension (PAH). MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells.